biostudies-literatureUnknown32(2)Wiegand REWe evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.Emerging infectious diseases246-249https://www.ebi.ac.uk/biostudies/studies/S-EPMC12928231biostudies-literatureEffectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events.PMC12928231Sung HMKautz ALink-Gelles RMak JChillarige YWiegand RENajdowski MLai YPayne ABZhang YChen YChavez AJiao YfalseEffectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events.We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.2026-01-01T00:00:00Z2026 Feb2026-07-16T17:45:06.793Z2026-07-09T11:09:41.124ZS-EPMC129282314171484010.3201/eid3202.251520